Attgeno Overview
- Year Founded
-
2005
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$1.44M
- Investors
-
8
Attgeno General Information
Description
Developer of nitric oxide-donating drugs designed to selectively treat acute blood pressure in the lungs. The company's drug is a blood vessel-inducing pharmaceutical based on nitric oxide-containing substances with unique properties that pass through the blood to the lungs and lower the pressure in the lung cycle by locally extending the blood vessels, enabling doctors to treat the life-threatening condition of their patients.
Contact Information
Website
www.attgeno.comCorporate Office
- Fogdevreten 2A
- 171 65 Solna
- Sweden
Corporate Office
- Fogdevreten 2A
- 171 65 Solna
- Sweden
Attgeno Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 26-Oct-2023 | $1.44M | Completed | Clinical Trials - Phase 2 | ||
| 7. Later Stage VC | 01-Jul-2022 | Completed | Clinical Trials - Phase 2 | |||
| 6. Later Stage VC | 01-Jan-2021 | Completed | Generating Revenue | |||
| 5. Grant | 01-Oct-2020 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC | 01-Apr-2020 | Completed | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC | 22-May-2018 | Completed | Clinical Trials - Phase 1 | |||
| 2. Accelerator/Incubator | 01-Jan-2017 | Completed | Clinical Trials - Phase 1 | |||
| 1. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 |
Attgeno Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preference | ||||||||
| Preference | ||||||||
| Preference | ||||||||
| Preference | 36,750 | $53.99 | $53.99 | 1x | $53.99 | 13.03% | ||
| Preference | 93,562 | $33.88 | $33.88 | 1x | $33.88 | 33.17% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Attgeno Patents
Attgeno Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024260728-A1 | Mono- and bis-nitrosylated propanediols for use in the treatment of a thromboembolic disease | Pending | 27-Apr-2023 | ||
| EP-4701632-A1 | Mono- and bis-nitrosylated propanediols for use in the treatment of a thromboembolic disease | Pending | 27-Apr-2023 | ||
| WO-2024223950-A1 | Mono- and bis-nitrosylated propanediols for use in the treatment of a thromboembolic disease | Inactive | 27-Apr-2023 | ||
| GB-202306258-D0 | New medical uses | Inactive | 27-Apr-2023 | ||
| JP-7943286-B2 | Mono and bisnitrosylated propanediols for therapeutic use | Active | 27-May-2020 | A61K31/04 |
Attgeno Signals
Attgeno Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Arbona | PE/Buyout | Minority | ||
| Eir Ventures | Venture Capital | Minority | ||
| Medtech4Health | Not-For-Profit Venture Capital | |||
| SWElife | Government | |||
| Vinnova | Government |
Attgeno FAQs
-
When was Attgeno founded?
Attgeno was founded in 2005.
-
Where is Attgeno headquartered?
Attgeno is headquartered in Solna, Sweden.
-
What is the size of Attgeno?
Attgeno has 8 total employees.
-
What industry is Attgeno in?
Attgeno’s primary industry is Drug Discovery.
-
Is Attgeno a private or public company?
Attgeno is a Private company.
-
What is the current valuation of Attgeno?
The current valuation of Attgeno is .
-
What is Attgeno’s current revenue?
The current revenue for Attgeno is .
-
How much funding has Attgeno raised over time?
Attgeno has raised $12.9M.
-
Who are Attgeno’s investors?
Arbona, Eir Ventures, Medtech4Health, SWElife, and Vinnova are 5 of 8 investors who have invested in Attgeno.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process